For how we live.
A Shionogi-funded randomised trial found that giving household contacts a five-day course dropped the rate of symptomatic Covid from 9.0% to 2.9%, with no severe cases in either group.
A US analysis of the 2025-2026 vaccines targeting the LP.8.1 lineage found both an mRNA-1283 and a BNT162b2 shot reduced COVID hospitalisation in older adults, with the strongest effect in those aged 75 and over.
Two randomised UK trials tested giving the vaccines together. Systemic reactions stayed mostly mild and immune responses held up, though one trial saw more sore arms and a dip in COVID antibodies with co-administration.
The two most-prescribed respiratory antivirals sit at opposite ends of the evidence. One shortens flu by less than a day on average; the other cut serious outcomes sharply — but only in the group at real risk.
A real condition with a formal case definition, a measurable population-level burden, and — so far — no treatment proven to reverse it. What the studies do and do not establish.
Every vaccine does the same job — teach the immune system to recognise a pathogen before it arrives. What differs is how they show it the target: live, inactivated, protein, viral vector, or mRNA.
JAMA published paired systematic reviews for the coming respiratory season. Both found vaccines reduced hospitalisation across age groups, with no new safety signals, though protection wanes over time.
Xocova is taken after a known exposure, not after symptoms appear. In a 2,041-person trial it cut symptomatic infection by 67% through day 10.
A Lancet study across 547,000 adults and 925 infectious diseases finds obesity raises the risk of severe infection across almost every pathogen type. The global estimate rests on modelling, not on the cohorts themselves.
An 11,018-measurement study in 24 English intensive care units found false negative rates up to 35.3 percentage points higher in patients with darker skin tones. A neonatal study published two days later did not.
The committee meets 18-19 September on COVID-19, hepatitis B and MMRV vaccines. RSV was dropped two days before. Adopted recommendations carry insurance and Vaccines for Children consequences.
A Federal Register notice on 9 June listed eleven vaccine topics and ten scheduled votes over three days. An amended notice on 24 June listed seven topics, three votes and two days.